The burden of patent ductus arteriosus (PDA) continues to be significant. In view of marked
differences in preterm infants versus more mature, term counterparts (viewed on a …

In many preterm infants, the ductus arteriosus remains patent beyond the first few days of
life. This prolonged patency is associated with numerous adverse outcomes, but the extent …

Preterm infants are at increased risk for patent ductus arteriosus (PDA). Prolonged exposure
to PDA may be deleterious and has been associated with neonatal morbidity and mortality …

The ductus arteriosus is likely to close without treatment in most infants born at gestational
age (GA)> 28 weeks (73%), and those with birth weight> 1000 g (94%). However, the rates …

Background Patent ductus arteriosus (PDA), the most commonly diagnosed cardiovascular
condition in preterm infants, is associated with increased mortality and harmful long-term …

The use of prophylactic indomethacin in very preterm infants is controversial. The last
randomized controlled trial (RCT) to study this therapy enrolled infants over 20 years ago …

Objective Evaluate predictors of successful PDA closure following acetaminophen treatment.
Study design Retrospective cohort study of≤ 30 weeks GA infants born from 1 January 2013 …

Background Patent ductus arteriosus (PDA) is associated with significant morbidity and
mortality in preterm infants. Cyclooxygenase inhibitors (COX‐I) may prevent PDA‐related …

In many preterm infants, the ductus arteriosus remains patent beyond the first few days of
life. This prolonged patency is associated with numerous adverse outcomes, but the extent …

In many preterm infants, the ductus arteriosus remains patent beyond the first few days of
life. This prolonged patency is associated with numerous adverse outcomes, but the extent …